Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · CONCORDBIO

CONCORDBIO

HealthcarePharmaceuticals & Biotechnology₹11739 cr market cap
₹556.40 ▼ -0.82% today As of 19 Nov 2026
52-week low ₹554.8052-week high ₹1587.50

-64.7% from the 52-week high · +1.1% above the low

Concord Biotech Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-08-18. Concord Biotech Limited is an India-based research and development driven biopharma company. The firm is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The firm manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. The company manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. The company also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The firm provides products in the critical care, immunology, nephrology, and transplant medicine segments.

The short version. CONCORDBIO reported revenue of ₹309 crore for Sep 2026, up 25.1% from a year earlier. Net profit was ₹71 crore (up 10.9% year on year). Return on equity was 12.9% in Mar 2026. Promoter holding was 44.09% in Sep 2026, up 0.01 points over 8 quarters.

1 · The price

How has the stock traded?

CONCORDBIO trades 64.7% below its 52-week high and 1.1% above its 52-week low.

Change over period: —

1M-56.4%
3M-64.7%
6M-49.7%
1Y-62.6%

2 · The business

Is it growing?

Sales, year on year+25.1%

Sep 2026 revenue of ₹309 cr.

Profit, year on year+10.9%

Sep 2026 net profit of ₹71 cr.

Net margin22.9%

2.8 pts lower than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue309257326278247204430244
Net profit71598964644414076
Net margin %22.922.727.223.225.721.632.731.1
EPS (₹)3.382.84.243.083.042.116.713.63

Annual

FY2026FY2025FY2024
Revenue105512001017
Net profit261372308
Net margin %24.731.030.3
EPS (₹)12.4717.7614.73

3 · The quality

How well does it turn capital into profit?

Return on equity was 12.9% in Mar 2026; debt to equity is 0.00.

Profitability · 3 years

Returns and margins

Mar 2026Mar 2025Mar 2024
Return on equity %12.920.520.2
Return on capital %16.626.826.4
EBITDA margin %37.644.344.3
Net margin %23.629.929.3

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.00
Interest cover1207.7x
Current ratio7.39
P/E ratio41.7

4 · The owners

Who holds it, and are they adding?

Promoter holding44.09%

Up 0.01 pts over 8 quarters.

Foreign institutions7.28%

Down 1.05 pts over 8 quarters.

Domestic institutions10.95%

Up 1.29 pts over 8 quarters.

Mutual fund schemes61

+14 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter44.0844.0844.0844.0844.0844.0844.0844.09+0.01
FII8.339.359.118.037.587.87.527.28-1.05
DII9.669.168.879.559.589.229.3610.95+1.29
Public37.9337.4137.9538.3338.7638.939.0337.68-0.25

Mutual fund holdings · Oct 2026

61 schemes hold this stock

47 the month before.

  • DSP Healthcare Fund2.46% of NAV
  • SBI Healthcare Opportunities Fund1.97% of NAV
  • Baroda BNP Paribas Health and Wellness Fund1.83% of NAV
  • DSP Small Cap Fund1.61% of NAV
  • Baroda BNP Paribas Innovation Fund1.18% of NAV
  • EDELWEISS SMALL CAP FUND1.05% of NAV
  • ITI Flexi Cap Fund0.87% of NAV
  • SBI Balanced Hybrid Fund0.75% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for CONCORDBIO are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about CONCORDBIO

What is the CONCORDBIO share price?

CONCORDBIO (CONCORDBIO) last closed at ₹556.40, down 0.82% on the day. Its 52-week range is ₹554.80 to ₹1,587.50.

What is the market cap of CONCORDBIO?

CONCORDBIO has a market capitalisation of about ₹11,739 crore. Its price-to-earnings ratio is 41.7.

How are CONCORDBIO's latest results?

CONCORDBIO reported revenue of ₹309 crore for Sep 2026, up 25.1% from a year earlier. Net profit was ₹71 crore (up 10.9% year on year). Return on equity was 12.9% in Mar 2026. Promoter holding was 44.09% in Sep 2026, up 0.01 points over 8 quarters.

Who owns CONCORDBIO?

As of Sep 2026, shareholding was: Promoter 44.09%, FII 7.28%, DII 10.95%, Public 37.68%.

How many mutual funds hold CONCORDBIO?

61 mutual fund schemes held CONCORDBIO in October 2026. That compares with 47 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 03 Sep 2025 · Final Dividend - Rs. 10.7
  • 21 Jun 2024 · Dividend - Rs. 8.75

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.